---
title: "Cerus Corporation (CERS.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CERS.US/overview.md"
symbol: "CERS.US"
name: "Cerus Corporation"
parent: "https://longbridge.com/en/quote/CERS.US.md"
datetime: "2026-04-17T10:17:04.870Z"
locales:
  - [en](https://longbridge.com/en/quote/CERS.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CERS.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CERS.US/overview.md)
---

# Cerus Corporation (CERS.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | US Market |
| Address | 1220 Concord Avenue, Suite 600, Concord, California, United States |
| Website | [www.cerus.com](https://www.cerus.com) |

## Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment.

## Key Executives

| Name | Title |
|------|-------|
| William M. Greenman | President, CEO & Chairman |
| Kevin D. Green | VP of Finance & CFO |
| Vivek K. Jayaraman | Chief Operating Officer |
| Chrystal N. Jensen | Chief Legal Officer, General Counsel & Secretary |
| Richard J. Benjamin | Chief Medical Officer |
| Eric H. Bjerkholt | Independent Director |
| Jami K. Dover Nachtsheim | Independent Director |
| Ann Lucena | Independent Director |
| Franklin R. Witney | Lead Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| BlackRock, Inc. | 11.41% | 2025-12-31 |
| ARK Investment Management LLC | 9.47% | 2025-12-31 |
| The Vanguard Group, Inc. | 5.81% | 2025-12-31 |
| Baker Bros. Advisors LP | 5.21% | 2025-12-31 |
| Soleus Capital Management, L.P. | 5.11% | 2026-03-23 |
| Wasatch Advisors LP | 2.84% | 2025-12-31 |
| Nikko Asset Management Co., Ltd. | 2.45% | 2025-12-31 |
| Silvercrest Asset Management Group LLC | 2.44% | 2025-12-31 |
| Geode Capital Management, LLC | 2.34% | 2025-12-31 |
| Senvest Management, LLC | 2.06% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Blood Safety | 206133000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Cerus Corporation Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Blood Safety",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 124723000 | 60.51% |
| Other Countries | 60212000 | 29.21% |
| France | 21198000 | 10.28% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**